Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.76 |
| ▸ | RAB9A | P51151 | 7/20 | 0.76 |
| ▸ | NPC1 | O15118 | 6/20 | 0.76 |
| ▸ | IKBKB | O14920 | 5/20 | 0.76 |
| ▸ | CASP3 | P42574 | 2/20 | 0.76 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.76 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.76 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.61 |
| ▸ | TUBB | P07437 | 2/20 | 0.61 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.61 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.61 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070140 | 0.89 | MAPT (0.78) | MAPTKDM4ERAB9ANPC1IKBKB | |
| SCHEMBL5195941 | 0.88 | KDM4E (0.76) | MAPTKDM4ERAB9ANPC1IKBKB | |
| SCHEMBL1531346 | 0.87 | MAPT (1.00) | MAPTKDM4ERAB9ANPC1IKBKB | |
| SCHEMBL1724239 | 0.87 | IKBKB (1.00) | MAPTKDM4ERAB9ANPC1IKBKB | |
| SCHEMBL431794 | 0.86 | MAPT (0.74) | MAPTKDM4ERAB9ANPC1IKBKB | |
| SCHEMBL17268776 | 0.85 | MAPT (0.80) | MAPTKDM4ERAB9ANPC1IKBKB | |
| Hydrochloric Acid SCHEMBL8864118 | 0.85 | MAPT (0.72) | MAPTKDM4ERAB9ANPC1IKBKB | |
| SCHEMBL16425576 | 0.84 | MAPT (0.56) | MAPTKDM4ERAB9ANPC1IKBKB | |
| SCHEMBL14975506 | 0.84 | KDM4E (0.71) | MAPTKDM4ERAB9ANPC1IKBKB | |
| SCHEMBL5192819 | 0.84 | MAPT (0.71) | MAPTKDM4ERAB9ANPC1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989433-B2 | Substituted thieno[3,2-D]pyrimidines as melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090298794-A1 | HYDROXY SUBSTITUTED THIENO PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-7268164-B2 | Anti-epileptogenic agents | QUEENS UNIVERSITY AT KINGSTON (CA) | 2007-09-11 | — | — | US | disclosed |
| CN-1774635-A | Anti-epileptogenic agents | UNIV KINGSTON (CA) | 2006-05-17 | — | — | CN | disclosed |
| US-6930112-B2 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2005-08-16 | — | — | US | disclosed |
| US-20030229144-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2003-12-11 | — | — | US | disclosed |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | QUEEN'S UNIVERSITY AT KINGSTON AND NEUROCHEM, INC. | 2003-10-16 | — | — | US | disclosed |
| US-20020025949-A1 | Anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON | 2002-02-28 | — | — | US | disclosed |
| US-6306909-B1 | AMINOACID DERIVATIVES AND ESTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-23 | — | — | US | disclosed |
| EP-0969823-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998040055-A2 | ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229144-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | MAPT 1914/4885KDM4E 1626/4885RAB9A 1636/4885 |
| US-20030194375-A1 | Administering 3-aminopropionic acid derivative as anticonvulsant | SLC1A2, SLC1A1, SLC1A3 | MAPT 1038/4885KDM4E 1615/4885RAB9A 1903/4885 |
| US-20020025949-A1 | Anti-epileptogenic agents | CA3, GAP43, GRIK5 | MAPT 1914/4885KDM4E 1626/4885RAB9A 1636/4885 |
| US-20090298794-A1 | HYDROXY SUBSTITUTED THIENO PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MC1R, MCHR2 | MAPT 3249/4885KDM4E 2566/4885RAB9A 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.